Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Study:

Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian epithelial or primary peritoneal cavity cancer.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Drug: capecitabine Phase 2

Verified by Gynecologic Oncology Group November, 2005

Sponsored by: Gynecologic Oncology Group
Information provided by: Gynecologic Oncology Group
ClinicalTrials.gov identifier: NCT00006812

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Agustin Garcia, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site